Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stalevo versus immediate-release carbidopa/levodopa crossover ERP study in Parkinson's disease
2007-003134-42Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levodopa and nacom in Parkinson's disease (PD) (2 arms), sponsored by Novartis. Primary endpoint: Mean latency of the P300 component of event-related potentials at Cz 4 hours post-levodopa administration. Started Feb 2008; status: completed.
02
Drugs
levodopanacom
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-003134-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003134-42.